Komori
Astellas Pharma (4503) · InitiativeAchieved

Consolidation of European research and development functions in Japan and the United States

First written in FY2018. 1 of 2 entries say "Achieved", first in FY2019. Latest entry: FY2019.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20182018: 120182019: 12019
Same theme, other companies
Consolidation of European R&D Functions in Japan and the United StatesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2019AchievedAnnual report

    「研究開発拠点を日本及び米国に集約しました。」

    欧州研究開発機能を日本及び米国へ集約する組織再編を完了した。
  2. FY2018First statedAnnual report

    「当連結会計年度の「リストラクチャリング費用」の主なものは、欧州における研究開発機能を日本と米国に集約する事によるものです。」

    研究開発機能を欧州から日本・米国へ集約する組織再編を実施し、リストラクチャリング費用として開示した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.